COMMIT: What does participating involve for me?

Study design

COMMIT is an open-label study.

An open-label study means both the researcher and the participant will know the treatment they are receiving.

Participants in this study will be randomly assigned to get either Atezolizumab or Atezolizumab combined with FOLFOX6 and Bevacizumab.

Treatment details

Atezolizumab and Bevacizumab are given intravenously, which means the medicine is delivered directly into your bloodstream through an IV or port. 

FOLFOX6 is a chemotherapy regimen made up of 3 drugs, 5 Fluorouracil (5-FU), Leucovorin, and Oxaliplatin, all commonly used in colorectal cancer treatment. They are given intravenously,  which means the medicine is delivered directly into your bloodstream through an IV or port. 

In the COMMIT trial, everyone in the study will get Atezolizumab as an infusion once every two weeks. Participants who take part in the study who also get FOLFOX6 and Bevacizumab will get them as infusions once every 2 weeks. Cycles for all treatments except Oxaliplatin will continue until a person’s cancer worsens, a person experiences a side effect that requires treatment to stop, or they decide they no longer want to participate in the trial. Oxaliplatin treatments will continue for up to 10 cycles, or until a person’s cancer worsens, a person experiences a side effect that requires treatment to stop, or they decide they no longer want to participate in the trial.